Industry news 🗞 Eli Lilly and Company wins long-awaited FDA approval for Alzheimer’s drug, donanemab, which will be marketed as Kisunla. Read the full story here: https://lnkd.in/ew3w8MdM #alzheimers #fda #lifesciences #industrynews #pharmanews
Mix Talent’s Post
More Relevant Posts
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Eli Lilly wins long-awaited approval for Alzheimer’s drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #healthcare #biotech
Eli Lilly wins long-awaited approval for Alzheimer’s drug
https://endpts.com
To view or add a comment, sign in
-
Thoughts on this? >> Eli Lilly wins long-awaited approval for Alzheimer’s drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #healthcare #productmarketing
Eli Lilly wins long-awaited approval for Alzheimer’s drug
https://endpts.com
To view or add a comment, sign in
-
Our latest regulatory strategy webinar, "Obtaining Orphan Drug Designations for Rare Disease Treatments" is now available to view on-demand. This free, one-hour webinar can be accessed at: https://ow.ly/1FOp50Stl6Q. This webinar is the second installment of our Navigating the FDA Roadmap Workshop series. If you missed the first webinar about understanding the IND process, you can watch it on-demand at: https://ow.ly/GKVf50StlgC. #drugdevelopment #lifesciences #webinar #regulatory #pharma #FDA #EMA #orphandiseases #orphandrugs #regulatoryaffairs #clinicaltrials
To view or add a comment, sign in
-
-
Latest Update (2023) on Leptomeningeal Metastases Pipeline Drugs: FDA Approvals, Clinical Trials, Therapeutic Insights, Mechanisms, Administration Routes Revealed by DelveInsight | NanoLiposome Plus #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech
Latest Update (2023) on Leptomeningeal Metastases Pipeline Drugs: FDA Approvals, Clinical Trials, Therapeutic Insights, Mechanisms, Administration Routes Revealed by DelveInsight | NanoLiposome Plus | ABNewswire
https://www.abnewswire.com/pressreleases
To view or add a comment, sign in
-
Setback for Alvogen in approval bid for IBS generic Alvogen subsidiary NORWICH PHARMACEUTICALS, INC. has faced a setback in securing US regulatory approval for its generic version of an irritable bowel syndrome (IBS) treatment. Read the full article here: https://ow.ly/Kv2w50Q3Nq4 #IBS #FDA #ANDA #medication #pharma #patent #US
To view or add a comment, sign in
-
-
🚀 Latest Pharma News You Can't-Miss! 🚀 ▶ Merck completes the acquisition of EyeBio, advancing Restoret™ for retinal diseases. ▶ The Affordable Prescriptions for Patients Act advances in the Senate to foster generic drug competition. ▶ Alembic Pharmaceuticals Limited receives USFDA tentative approval for Selexipag Injection to treat PAH. ▶ AbbVie seeks FDA and EMA approval for Upadacitinib to treat Giant Cell Arteritis. ▶ Federal court rejects Boehringer Ingelheim's challenge to Medicare drug price negotiation. 📲 Read the complete story at www.pharmanow.live Stay informed with the latest breakthroughs and regulatory updates! 📈✨ #PharmaNow #Merck #EyeBio #AlembicPharma #AbbVie #BoehringerIngelheim #PharmaNews #IndustryUpdate
To view or add a comment, sign in
-
Nektar Therapeutics has sued Eli Lilly over the Big Pharma's clinical development handling of the biotech's investigational autoimmune treatment. In its complaint, Nektar’s lawyers say the case “involves the all-too-familiar story of a large pharmaceutical company elevating profits over all else.” #nektar #elililly #lawsuit #bigpharma #pharma #biotech #drugdevelopment #autoimmunediseases
Nektar sues Lilly, claiming it hindered biotech’s autoimmune drug after buying Dermira
https://endpts.com
To view or add a comment, sign in
-
This latest case study summarizes how our flexible and agile #RTSM platform helped a sponsor navigate complex patient cohorts and adaptive study medication schedules, supporting successful FDA Orphan Drug Designation: https://lnkd.in/eSDQt-Dn
One of the keys is rapid implementation of mid-study protocol changes
https://www.signanthealth.com
To view or add a comment, sign in
-
Article explaining the new D2C channel of Eli Lilly and highlighting the main concerns about this healthcare model, directly offered by drug manufacturers. Are we on the right path?
In a new Viewpoint, Benjamin Rome, MD, MPH, discusses the launch of direct-to-consumer pharmacy LillyDirect from Eli Lilly, intended to add new options for patients to access the company’s drugs, including its newly approved antiobesity drug tirzepatide (Zepbound). https://ja.ma/49TD1OB
To view or add a comment, sign in
-